This episode, titled ‘Comparing Biologic Classes and Durability in Psoriasis,’ features panelists discussing how different biologic classes compare in achieving and sustaining remission in psoriasis, with a focus on both speed and durability of response. The faculty discussed how treatment paradigms have evolved as head-to-head clinical trial data have emerged, allowing for more direct comparisons between classes such as IL-17 and IL-23 inhibitors. Historically, IL-17 inhibitors have been associated with rapid onset of action, while IL-23 inhibitors have demonstrated durable long-term responses.

The expert faculty highlight that not all agents within a biological class perform identically. Differences in efficacy and durability within the same class have become more apparent through direct comparisons, prompting clinicians to reconsider traditional approaches to treatment sequencing. Rather than automatically switching to a different class when a patient has an inadequate response, there may be value in selecting another agent within the same class.

They emphasize the growing importance of nuanced, evidence-based decision-making in psoriasis care. With an expanding array of therapeutic options, clinicians must consider not only class-level characteristics but also individual drug performance. Ultimately, the discussion reinforces that both achieving and maintaining disease control along with personalized treatment strategies are essential for optimizing long-term outcomes.

In the next episode, ‘IL-17 Inhibition and Long-Term Outcomes in Psoriasis,’ the panelists explore the mechanistic differences within IL-17 inhibition and their implications for treatment outcomes in psoriasis. It also highlights the challenges of interpreting long-term clinical trial and real-world data when evaluating sustained disease control.